System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Maxime Fontanilles is an expert in Oncology at Centre Henri Becquerel (France). Maxime Fontanilles has authored 55 publications, the most recent in 2025, and is an investigator in 5 clinical trials, 1 of them ongoing. SLR score: 256 (community average: 125). How the SLR is computed.

LeadR Profile

Maxime Fontanilles Centre Henri Becquerel France
256 ScienceLeadR Reputation 256

Unlock

Register Login
Network Map

Oncology

Subspecialties: Neurology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2015 - 2026
Source: PubMed

Centre Henri Becquerel

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 55

Citations

Citations: 708 1st author: 14 Last author: 8 Unique author: 1

Main journals

Ann Oncol 7
J Clin Oncol 4
Acta Neuropathol Commun 3
Bull Cancer 3
Rev Neurol (Paris) 3

Best Journals

Ann Oncol 5
J Clin Oncol 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Proton therapy for adult type IDH-mutated glioma: Proglio-1, a multicenter retrospective study.
PMID 40764578 — radiotherapy, glioma, proton therapy, radiation oncology, retrospective studies, therapeutics		Radiat Oncol20250
Prognostic value of circulating HER2 extracellular domain in patients with HER2-positive metastatic breast carcinoma treated with TDM-1 (trastuzumab emtansine).
PMID 40754555 — breast neoplasms, neoplasms, biomarkers, maytansine, ado-trastuzumab emtansine, breast, multivariate analysis, trastuzumab		Clin Transl Oncol20250
Olaparib, Temozolomide, and Concomitant Radiotherapy for Partially Resected or Biopsy-Only Glioblastoma First-Line Treatment: Results from the OLA-TMZ-RTE-01 Phase I Study.
PMID 39882966 — radiotherapy, safety, temozolomide, neoplasms, biopsy, maintenance, chemoradiotherapy, glioblastoma, therapeutics		Clin Cancer Res20255
The clinical impact of EGFR alterations in elderly glioblastoma patients: results from a real-life cohort.
PMID 39549128 — aged, glioblastoma, nervous system neoplasms		J Neurooncol20240
Metabolic remodeling in glioblastoma: a longitudinal multi-omics study.
PMID 39394177 — neoplasms, multiple chronic conditions, biopsy, metabolomics, proteomics, glioblastoma, plasma		Acta Neuropathol Commun20245

Clinical Studies 5

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 2 2
N/A 1
Phase 1 1
Phase 3 1

By status:

Completed 3
Recruiting 2

By type:

Interventional 5

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 1
multicentric5to9 0
multicentricup10 2

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Randomized Trial of Delayed Radiotherapy in Patients Low grade Oligodendrogliomas Requiring a Treatment Other Than Surgery
NCT04702581 — radiotherapy, drug therapy, vincristine, procarbazine, therapeutics, oligodendroglioma, chemotherapy		Phase 3Recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS